Literature DB >> 3613884

Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man.

C Skak, S Keiding.   

Abstract

Liver blood flow (Q) is often measured by constant infusion of ICG (i), concentration measurements in an artery (A) and a hepatic vein (V): Q = (A-V)/A. Some authors use ICG clearance, Cl = i/A, as a measure of Q assuming complete hepatic extraction. During the infusion, the ICG concentration often increases. The importance of this for calculated values of Q and Cl was examined, and the use of Cl as a measure of Q was reevaluated. ICG was given as 0.06-0.20 mumol/min to 52 subjects with liver disease, and about 0.20 mumol/min to 86 subjects with no liver disease. ICG concentration increased steeply during the first 90 min after start of the infusion; thereafter the increment was constant as evaluated in successive 40-min periods in eleven 320-min studies (analysis of variance P greater than 0.5); on average, 6 +/- 1% per hour (+/- SD). Q was not time-dependent (P greater than 0.5). ICG clearance decreased significantly, on average 5 +/- 2% per hour (+/- SD). Hepatic extraction fraction, (A-V)/A, (measurement period 90-130 min) was 0.34 +/- 0.21 in liver patients (+/- SD) and 0.61 +/- 0.80 in controls. Cl and Q were positively correlated in both groups but with substantial scatter. Thus, not only is the calculated ICG clearance time-dependent but the extraction fraction is further so low and variable, that any use of ICG clearance as a measure of liver flow is not justified.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3613884     DOI: 10.1111/j.1600-0676.1987.tb00336.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  21 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Mesenteric, coeliac and splanchnic blood flow in humans during exercise.

Authors:  M J Perko; H B Nielsen; C Skak; J O Clemmesen; T V Schroeder; N H Secher
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

Review 4.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

5.  Hepatic blood flow measurements and indocyanine green kinetics in a chronic dog model.

Authors:  A Skerjanec; D W O'Brien; T K Tam
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

6.  Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.

Authors:  Jens-Otto Clemmesen; Annamaria Giraldi; Peter Ott; Kim Dalhoff; Bent-Adel Hansen; Fin-Stolze Larsen
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

7.  The kinetics of continuously infused indocyanine green in the pig.

Authors:  P Ott; L Bass; S Keiding
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

8.  Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.

Authors:  P A Soons; A De Boer; A F Cohen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

9.  Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper S Mikkelsen; Kim Frisch; Gerda E Villadsen; Susanne Keiding
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

10.  Hepatic ethanol elimination kinetics in patients with cirrhosis.

Authors:  Gitte Dam; Michael Sørensen; Ole Lajord Munk; Susanne Keiding
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.